At the Cancer Vaccine Institute, our team is at the forefront of cancer vaccine development — and we’re creating a world in which the disease is no longer a threat. 

We’re doing that by creating vaccines to treat and prevent cancer. Activating the immune system with vaccines is the best and only tool for completely eliminating cancer at the single-cell level. 

With our help, patients can better fight and fend off cancer, even years after their initial vaccine. 

The vaccines work by targeting proteins that are found at much higher levels in cancer cells than in healthy cells. This revolutionary approach is safer, non-toxic, and elicits a strong immune response. We have more than 10 vaccines in development with three vaccines in Phase II clinical trials. 
 

Results from our Phase I clinical trial in HER2+ breast cancer showed that the vaccine is safe and creates a cancer-destroying immune response. In fact, 85% of our patients with advanced stage HER2+ breast cancer are alive 10 years after vaccination with the median dose of our HER2 ICD vaccine. Without the vaccine, it would be expected that only half of the patients would be alive 4.5 years after diagnosis. 
 

In another study, more than 50% of patients with advanced stage ovarian cancer are alive more than eight years after receiving our IGFBP-2 vaccine. Compare this to an expected survival rate of 50% 18 months after diagnosis without the vaccine.

Immunology isn't a novel scientific discipline. What is groundbreaking is how we're using it: to create a world where a cancer diagnosis is no longer terrifying. 

Our vaccines are inexpensive to produce and administer, ensuring equitable access to this lifesaving treatment.

Our immediate focus is on the cancers that make up more than half of diagnoses and deaths in the United States. We currently have vaccines to treat and prevent cancer and/or its recurrence for breast, ovarian, colon, lung, bladder, and prostate cancer. We look forward to expanding into other cancers as well.